Central serous chorioretinopathy and antiphospholipid syndrome: Three cases report-Reference-Cited by-同舟云学术

Central serous chorioretinopathy and antiphospholipid syndrome: Three cases report

Published:2020-12-13 Issue:3 Volume:30 Page:514-517
ISSN:0961-2033
Container-title:Lupus
language:en
Short-container-title:Lupus

Author:

Billoir Paul¹^ORCID,Michon Adrien²,Darnige Luc³⁴

Affiliation:

1. Vascular Hemostasis Unit, Rouen University Hospital, Normandie Univ, UNIROUEN, INSERM U1096, Rouen, France

2. Service de médecine interne, hôpital européen Georges-Pompidou, Université Paris Descartes, Assistance Publique-Hôpitaux de Paris, 20, Paris, France

3. Service d'hématologie Biologique, Hôpital Européen Georges Pompidou, AP-HP, Paris, France

4. INSERM UMR-S1140, Paris, France

Abstract

Antiphospholipid syndrome (APS) is an acquired autoimmune disease characterized by recurrent venous or arterial thrombotic events and pregnancy morbidity, with persistently presence of antiphospholipid antibodies (aPL). We report three cases of central serous chorioretinopathy (CSC) associated with APS.

Publisher

SAGE Publications

Subject

Rheumatology

Link

http://journals.sagepub.com/doi/pdf/10.1177/0961203320979736

Reference16 articles.

1. Antiphospholipid syndrome

2. Ocular manifestations in antiphospholipid syndrome

3. Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients

4. Ocular manifestations of the antiphospholipid syndrome

5. Ophthalmologic manifestations in primary antiphospholipid syndrome patients: A cross-sectional analysis of a primary antiphospholipid syndrome cohort (APS-Rio) and systematic review of the literature

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Methandienone contributes directly on develop central serous chorioretinopathy in athletes;3RD INTERNATIONAL SCIENTIFIC CONFERENCE OF ALKAFEEL UNIVERSITY (ISCKU 2021);2022

2. Ophthalmologic manifestations in patients with antiphospholipid antibodies: Beware of iatrogenic complications;Lupus;2021-07-20